Gallardo Christian Aledia, Wong Lester Jun Long, Sum Christina Lai Lin, Goh Liuh Ling, Ong Kiat Hoe
Department of Haematology, Tan Tock Seng Hospital, Singapore, Singapore.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
J Hematol. 2022 Feb;11(1):29-33. doi: 10.14740/jh943. Epub 2022 Feb 26.
Factor VII (FVII) deficiency manifests as prolonged prothrombin time (PT) and reduced FVII activity. We report a case of an asymptomatic 60-year-old gentleman with discrepancies in PT and FVII coagulant activity levels (FVII:C) on three different thromboplastin reagents used. Further sequence analysis on genomic DNA showed double heterozygosity for c.1025G>A p.Arg342Gln and c.194C>G p.Ala65Gly in the gene. To date, p.Ala65Gly in exon 2 of the gene represents a novel variant in patients with FVII deficiency and is classified as likely pathogenic. Computational prediction tools support a deleterious effect on the gene. The genotype-phenotype association and the clinical significance of this exon 2 missense variant is proposed in this case report.
因子 VII(FVII)缺乏表现为凝血酶原时间(PT)延长和 FVII 活性降低。我们报告了一例 60 岁无症状男性病例,其使用三种不同的凝血活酶试剂时 PT 和 FVII 凝血活性水平(FVII:C)存在差异。对基因组 DNA 的进一步序列分析显示该基因存在 c.1025G>A p.Arg342Gln 和 c.194C>G p.Ala65Gly 的双重杂合性。迄今为止,该基因外显子 2 中的 p.Ala65Gly 在 FVII 缺乏患者中代表一种新的变异,被分类为可能致病。计算预测工具支持该变异对基因有有害影响。本病例报告提出了该外显子 2 错义变异的基因型 - 表型关联及临床意义。